Trial Profile
Phase Ib dose-escalation trial of fasoracetam [NFC-1] in mGluR network mutation positive adolescents with attention deficit hyperactivity disorder
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2016
Price :
$35
*
At a glance
- Drugs Fasoracetam (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 17 Feb 2016 According to a Medgenics media release, data was presented at the 62nd American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting
- 11 Sep 2015 New trial record
- 09 Sep 2015 Results will be presented at the 2015 American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, according to a Medgenics media release.